Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

-8.0%

Nov 6 3:46 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	4/29/2014 11:41:05 AM
	of 13111

Provectus News PV-10 Treatment Decreases Melanoma Cells in Tumors Tuesday April 29, 2014 An article appearing in Cancer Watch, Vol. 23 61-62 (2014), reports on data presented by Moffitt Cancer Center researchers demonstrating significant decreases in melanoma cells in injected tumors and uninjected bystander tumors. The researchers showed that these changes in tumors were accompanied by increased populations of CD3, CD4 and CD8 T cells along with NKT cells in peripheral blood. T cells from one patient were purified and exhibited increased interferon-gamma expression when exposed to the patient's pre-treatment melanoma cells. With the permission of the publisher, the article is available at pvct.com on the Provectus website. Provectus signs consulting agreement with Washington, D.C. firm Tuesday April 29, 2014 The April 28, 2014 edition of the Knoxville News-Sentinel includes a news brief reporting that Provectus has entered into a consulting agreement with the Washington, DC-based firm Roberti+White LLC to assist in developing a public policy strategy for PV-10. The article is available at knoxnews.com on the Knoxville News-Sentinel website.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next